(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
26 August 2010 (26.08.2010)

PCT

(10) International Publication Number
WO 2010/096434 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
G01N 33/50 (2006.01) *A61K 39/395* (2006.01)
G01N 33/574 (2006.01)

(21) International Application Number:
PCT/US2010/024407

(22) International Filing Date:
17 February 2010 (17.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
12/388,504 18 February 2009 (18.02.2009) US

(71) Applicant *(for all designated States except US)*: **LUDWIG INSTITUTE FOR CANCER RESEARCH** [US/US]; 605 Third Avenue, New York, New York 10158 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **OLD, Lloyd J.** [US/US]; 600 West End Avenue, Apt. 6D, New York, New York 10024 (US). **JONHS, Terrance, Grant** [AU/AU]; Monash Institute of Medical Research, 27-31 Wright Street, Clayton 3168 (AU). **PANOUSIS, Con** [AU/AU]; 77 Erskine Road, Macleod. 3085, Melbourne, VIC (AU). **SCOTT, Andrew, Mark** [AU/AU]; 367 Cotham Road, Kew, VIC 3101 (AU). **RENNER, Christoph** [DE/DE]; Ringstr. 8, 66424 Homburg/Saar (DE). **RITTER, Gerd** [DE/US]; 430 East 63rd Street, Apt. 10A, New York, New York 10021 (US). **JUNGBLUTH, Achim** [DE/US]; 450 East 63rd Street, Apt. 9D, New York, New York 10021 (US). **STOCKERT, Elizabeth** [AT/AT]; Plankengasse 1/8, 1010 Wien (AT). **COLLINS, Peter** [IE/GB]; 67 Panton Street, Cambridge, CB2 IHL (GB). **CAVENEE, Webster, K.** [US/US]; 4657 Vista de Ia Tierra, Del Mar, California 92014 (US). **HUANG, Huei-Jen Su** [US/US]; P.O. Box 247, Rancho Santa Fe, California 92067 (US). **BURGESS, Antony Wilks** [AU/AU]; 32 Range Street, Camberwell, Victoria, 3124 (AU). **NICE, Edouard, Collins** [AU/AU]; 9, Odessa Street, St. Kilda, Victoria 3182 (AU). **MURRAY, Anne** [US/US]; 1275 York Avenue, New York, NY 10021 (US). **MARK, George** [US/US]; 1275 York Avenue, New York, NY 10021 (US).

(74) Agent: **REININGER, Irene M.**; Abbott Laboratories, Dept. 0377, Bldg. AP6A-1A, 100 Abbott Park Road, Abbott Park, Illinois 60064-6008 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
27 January 2011

(54) Title: SPECIFIC BINDING PROTEINS AND USES THEREOF

(57) Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

WO 2010/096434 A3